Table of Contents Author Guidelines Submit a Manuscript
Letter to the Editor
International Journal of Rheumatology
Volume 2015, Article ID 728610, 8 pages
http://dx.doi.org/10.1155/2015/728610
Review Article

The Role of Citrullinated Protein Antibodies in Predicting Erosive Disease in Rheumatoid Arthritis: A Systematic Literature Review and Meta-Analysis

1Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London SW10 7NH, UK
2Charing Cross Hospital, Imperial College Healthcare NHS Trust, Fulham Palace Road, London W6 8RF, UK

Received 16 November 2014; Revised 31 January 2015; Accepted 8 February 2015

Academic Editor: Ruben Burgos-Vargas

Copyright © 2015 A. A. Jilani and C. G. Mackworth-Young. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. L. Scott, “Radiological progression in established rheumatoid arthritis,” The Journal of Rheumatology, vol. 31, supplement 69, pp. 55–65, 2004. View at Google Scholar · View at Scopus
  2. D. van der Woude, S. Rantapää-Dahlqvist, A. Ioan-Facsinay et al., “Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis,” Annals of the Rheumatic Diseases, vol. 69, no. 8, pp. 1554–1561, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Wegner, K. Lundberg, A. Kinloch et al., “Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis,” Immunological Reviews, vol. 233, no. 1, pp. 34–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Bizzaro, “Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis,” Clinical Chemistry and Laboratory Medicine, vol. 45, no. 2, pp. 150–157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. E. R. Vossenaar, A. J. W. Zendman, W. J. van Venrooij, and G. J. M. Pruijn, “PAD, a growing family of citrullinating enzymes: Genes, features and involvement in disease,” BioEssays, vol. 25, no. 11, pp. 1106–1118, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Makrygiannakis, E. Af Klint, I. E. Lundberg et al., “Citrullination is an inflammation-dependent process,” Annals of the Rheumatic Diseases, vol. 65, no. 9, pp. 1219–1222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Nakayama-Hamada, A. Suzuku, and K. Kubota, “Comparison of enzymatic properties between hPAD12 and hPAD14,” Biochemical and Biophysical Research Communications, vol. 327, pp. 192–200, 2005. View at Publisher · View at Google Scholar
  8. E. R. Vossenaar, T. J. M. Smeets, M. C. Kraan, J. M. Raats, W. J. van Venrooij, and P. P. Tak, “The presence of citrullinated proteins is not specific for rheumatoid synovial tissue,” Arthritis and Rheumatism, vol. 50, no. 11, pp. 3485–3494, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Bang, K. Egerer, A. Gauliard et al., “Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis,” Arthritis and Rheumatism, vol. 56, no. 8, pp. 2503–2511, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Innala, H. Kokkonen, C. Eriksson, E. Jidell, E. Berglin, and S. Rantapää-Dahlqvist, “Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides,” Journal of Rheumatology, vol. 35, no. 6, pp. 1002–1008, 2008. View at Google Scholar · View at Scopus
  11. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 31, no. 3, pp. 315–324, 1988. View at Publisher · View at Google Scholar · View at Scopus
  12. M. W. Ropes, G. A. Bennett, S. Cobb et al., “Diagnostic criteria for rheumatoid arthritis 1958 revision,” Annals of the Rheumatic Diseases, vol. 18, no. 1, pp. 49–53, 1959. View at Google Scholar
  13. D. van der Heijde, “How to read radiographs according to the Sharp/van der Heijde method,” Journal of Rheumatology, vol. 26, no. 3, pp. 743–745, 1999. View at Google Scholar · View at Scopus
  14. A. Larsen, “How to apply larsen score in evaluating radiographs of rheumatoid arthritis in longterm studies?” Journal of Rheumatology, vol. 22, no. 10, pp. 1974–1975, 1995. View at Google Scholar · View at Scopus
  15. E. M. Dias, C. Lukas, R. Landewé, S. Fatenejad, and D. Van Der Heijde, “Reliability and sensitivity to change of the Simple Erosion Narrowing Score compared with the Sharp-van der Heijde method for scoring radiographs in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 67, no. 3, pp. 375–379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. Hayden, P. Côté, and C. Bombardier, “Evaluation of the quality of prognosis studies in systematic reviews,” Annals of Internal Medicine, vol. 144, no. 6, pp. 427–437, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. K. P. Machold, T. A. Stamm, V. P. K. Nell et al., “Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease,” Rheumatology, vol. 46, no. 2, pp. 342–349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Bukhari, W. Thomson, H. Naseem et al., “The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register,” Arthritis and Rheumatism, vol. 56, no. 9, pp. 2929–2935, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Kaltenhäuser, M. Pierer, S. Arnold et al., “Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis,” Rheumatology, vol. 46, no. 1, pp. 100–104, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Rojas-Villarraga, F. J. Diaz, E. Calvo-Páramo et al., “Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis,” Journal of Autoimmunity, vol. 32, no. 1, pp. 64–69, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. S. W. Syversen, G. L. Goll, D. van der Heijde et al., “Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study,” Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 345–351, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Mathsson, M. Mullazehi, M. C. Wick et al., “Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides,” Arthritis and Rheumatism, vol. 58, no. 1, pp. 36–45, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. B. A. Fisher, D. Plant, M. Brode et al., “Antibodies to citrullinated α-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 6, pp. 1095–1098, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. H. E. Mansour, K. M. Metwaly, I. A. Hassan, H.-A. A. Elshamy, and M. M. S. Elbeblawy, “Antibodies to mutated citrullinated vimentin in rheumatoid arthritis: diagnostic value, association with radiological damage and axial skeleton affection,” Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, vol. 3, pp. 33–42, 2010. View at Google Scholar · View at Scopus
  25. M. L. Hetland, K. Stengaard-Pedersen, P. Junker et al., “Radiographic progression and remission rates in early rheumatoid arthritis—MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial,” Annals of the Rheumatic Diseases, vol. 69, no. 10, pp. 1789–1795, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Plant and W. Thomson, “The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis,” Rheumatology, vol. 10, pp. 1093–1100, 2010. View at Google Scholar
  27. H. H. Kim, J. Kim, S.-H. Park, S.-K. Kim, O.-D. Kim, and J.-Y. Choe, “Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients,” Korean Journal of Internal Medicine, vol. 25, no. 2, pp. 201–206, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Sanmartí, E. Graell, M. L. Perez et al., “Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis,” Arthritis Research & Therapy, vol. 11, no. 5, article R135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. M. P. M. van der Linden, D. van der Woude, A. Ioan-Facsinay et al., “Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis,” Arthritis and Rheumatism, vol. 60, no. 8, pp. 2232–2241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Reneses, M. F. González-Escribano, A. Fernández-Suárez et al., “The value of HLA-DRB1 shared epitope, -308 tumor necrosis factor-α gene promoter polymorphism, rheumatoid factor, anti-citrullinated peptide antibodies, and early erosions for predicting radiological outcome in recent-onset rheumatoid arthritis,” Journal of Rheumatology, vol. 36, no. 6, pp. 1143–1149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Courvoisier, M. Dougados, A. Cantagrel et al., “Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study,” Arthritis Research & Therapy, vol. 10, article R106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. E. W. Karlson, L. B. Chibnik, J. Cui et al., “Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study,” Annals of the Rheumatic Diseases, vol. 67, no. 3, pp. 358–363, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Mewar, A. Coote, D. J. Moore et al., “Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis,” Arthritis Research and Therapy, vol. 8, no. 4, article R128, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. O. Meyer and P. Nicaise-Roland, “Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis,” Arthritis Research and Therapy, vol. 40, pp. 1186–1196, 2006. View at Google Scholar
  35. G. Boire, P. Cossette, A. J. de Brum-Fernandes et al., “Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis,” Arthritis Research & Therapy, vol. 7, no. 3, pp. R592–R603, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. S. M. Bongi, R. Manetti, D. Melchiorre et al., “Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA,” Autoimmunity, vol. 37, no. 6-7, pp. 495–501, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Lindqvist, K. Eberhardt, K. Bendtzen, D. Heinegård, and T. Saxne, “Prognostic laboratory markers of joint damage in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 64, no. 2, pp. 196–201, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. L. M. A. Jansen, D. van Schaardenburg, I. E. van der Horst-Bruinsma, R. J. van de Stadt, M. H. M. T. de Koning, and B. A. C. Dijkmans, “The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis,” Journal of Rheumatology, vol. 30, no. 8, pp. 1691–1695, 2003. View at Google Scholar · View at Scopus
  39. H. Orbach, B. Gilburd, C. M. Brickman, R. Gerli, and Y. Shoenfeld, “Anti-cyclic citrullinated peptide antibodies as a diagnostic test for rheumatoid arthritis and predictor of an erosive disease,” Israel Medical Association Journal, vol. 4, no. 11, pp. 892–893, 2002. View at Google Scholar · View at Scopus
  40. J. Vencovský, S. Macháček, L. Šedová et al., “Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 62, no. 5, pp. 427–430, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Baillet, C. Gaujoux-Viala, G. Mouterde et al., “Comparison of the efficacy of sonography, magnetic resonance imaging and conventional radiography for the detection of bone erosions in rheumatoid arthritis patients: a systematic review and meta-analysis,” Rheumatology (Oxford, England), vol. 50, no. 6, pp. 1137–1147, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. X. Jiang, L. A. Trouw, D. van der Woude et al., “Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies,” Annals of the Rheumatic Diseases, vol. 73, no. 10, pp. 1761–1768, 2014. View at Publisher · View at Google Scholar · View at Scopus